Bioverativ Inc. (BIVV) Tops Q3 EPS by 11c

Bioverativ Inc. (NASDAQ: BIVV) reported Q3 EPS of $0.80, $0.11 better than the analyst estimate of $0.69. Revenue for the quarter came in at $291.6 million versus the consensus estimate of $285.49 million.

For earnings history and earnings-related data on Bioverativ Inc. (BIVV) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c